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SHORT COMMUNICATION
The real-life number of neonatal doses of Bacille Calmette-Guérin vaccine in a
20-dose vial
Frederik Schaltz-Buchholzera*, Hannah Nørtoft Frankela* and Christine Stabell Benna,b,c
aResearch Center for Vitamins and Vaccines, Statens Serum Institut, Copenhagen, Denmark; bOPEN, Odense Patient data Explorative
Network, Odense University Hospital/Institute of Clinical Research, University of Southern Denmark, Odense, Denmark; cInstitute of
Clinical Research, University of Southern Denmark, Odense, Denmark
ABSTRACT
Background: Reducing vaccine wastage is important. Bacille Calmette-Guérin (BCG) vaccine
is produced in vials of 20 infant doses. The reconstituted vaccine is discarded after 4–6 hours.
Therefore, to reduce vaccine wastage, a 20-dose vial of BCG is often only opened if at least
10–12 infants are present, jeopardising BCG vaccination coverage and timely vaccination. We
observed that nurses were not able to withdraw 20 doses from the vials and aimed to
quantify how many doses could be obtained from these vials by experienced nurses under
real-life circumstances.
Methods: At the maternity ward of the national hospital in Guinea-Bissau, since 2002 the
same two nurses have been vaccinating all eligible children with BCG before discharge.
During a month in 2015, within a randomised trial comparing BCG-Denmark and BCG-
Russia, we registered how many doses the nurses were able to withdraw from the two
types of vaccine vials.
Results: The median number of doses which it was possible to withdraw from the vials was
13 (range 11–17): 13 (11–16) for BCG-Denmark (based on 39 vials) and 15 (12–17) for BCG-
Russia(based on 29 vials).
Conclusions: In real life, experienced nurses could only obtain 13–15 doses from the 20-dose vials.
Thus, vaccine wastage is much lower than assumed. Adjusting practice to the real-life number of
doses would immediately suggest vials should be opened if 7 rather than 10 infants are present. As
other studies have indicated that BCGmay have beneficial non-specific effects on overall mortality,
the potential gain by opening a 20-dose vial even for one child may be considerable.
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Background
Bacille Calmette-Guérin (BCG) vaccine, the live attenu-
ated vaccine against tuberculosis, is provided as a vial of
freeze-dried vaccine together with a vial containing 1ml
solvent. According to the manufacturers’ specifications,
one vial of reconstituted vaccine contains 1 ml, corre-
sponding to 10 doses for adults and children aged
12 months and over (0.1 ml) or 20 doses for infants
less than 12 months (0.05 ml). The reconstituted vac-
cine should be discarded after 4–6 hours [1,2].
Discarding remaining BCG vaccine after comple-
tion of a vaccine session, so-called ‘open vial wastage’,
is an important source of wastage. Though the World
Health Organization (WHO) states that ‘it is always
recommended to open a vial of vaccine for one infant
or a small number of infants’ [3], national vaccina-
tion programs are increasingly instructed to avoid
wastage. Countries receiving support from the
Global Alliance for Vaccines and Immunisations
have been requested to reduce their wastage rates to
15% for 20-dose formulations [3].
One way to reduce open vial wastage is to increase
the number of children vaccinated at each session [3].
Indeed, this is what is happening; in Guinea-Bissau
and other low-income countries, a vial of BCG is not
opened unless there are at least 10–12 infants eligible
for BCG vaccination present. In practical terms, this
is implemented by health centres having only one or
two BCG vaccination days (BCG-days) per week or
even per month. Mothers of children presenting on
other days are told to come back on a BCG-day. If
fewer than the required number of children are pre-
sent on a given BCG-day, all children are told to
come back on the next BCG-day. Such local policies
cause unnecessary delays in vaccination and are a
threat to obtaining full BCG vaccination coverage.
In order to calculate correct wastage rates, it is
important to know the real-life number of doses in
a 20-dose vial. In Guinea-Bissau, the Bandim Health
Project (BHP) has conducted several randomised
controlled trials (RCT) using BCG vaccine. For this
purpose, the BHP has implemented BCG vaccination
at the maternity ward of the national hospital, and
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since 2002, the same two skilled BCG vaccinators
have vaccinated all neonates eligible for BCG vaccine.
We used this set-up to test how many doses two
experienced vaccinators could obtain from two dif-
ferent types of 20-dose BCG vaccine preparations:
BCG-Denmark and BCG-Russia, both pre-qualified
vaccines used interchangeably by UNICEF.
Methods
In Guinea-Bissau, approximately 6,500 children/year are
delivered at the maternity ward of the national hospital.
Within an ongoing trial, BCG-Denmark (Statens
Serum Institut, Copenhagen, Denmark) and BCG-
Russia (Serum Institute of India, Pune, India) are
compared for their effect on overall morbidity within
the first 6 weeks of life. Healthy neonates delivered at
the maternity ward are randomised 1:1 to the two
vaccines at discharge, with an average enrolment rate
of 14 children per day. In addition, a smaller RCT at
the hospital’s neonatal intensive care unit randomises
neonates 1:1 to receive BCG-Denmark either at
admission or at discharge. The average inclusion
rate for this trial is three per day. Furthermore,
BCG may be given to infants born at the hospital
who did not participate in an RCT (due to lack of
consent or severe malformations).
One of the two vaccinators provide all vaccinations
on a given day. Vaccines are administered intradermally
using a SoloShot Mini auto-disabling 0.05 ml syringe
(Becton Dickinson, NJ, USA). After each vaccination,
the vaccinator stores the used syringes in a safe con-
tainer, one for BCG-Denmark and one for BCG-Russia.
The present study took place from 12 October–9
November 2015. At the end of each vaccination session,
the vaccinator counted the used syringes for each vial of
BCG opened. Subsequently, the vaccinator drew up any
excess vaccine doses left in each vial, using a new
0.05 ml BCG syringe for each dose, until no further
full 0.05 ml dose could be drawn. For each vial, the
vaccinator noted the number of doses used during the
vaccination session and the number of doses subse-
quently drawn from the vial. All procedures were super-
vised on a daily basis by a BHP staff member.
Ethical approval for the BCG trial was obtained
from the Guinean Ethical Committee; the Danish
ethical committee gave its consultative approval. No
permission was necessary for the present study,
which did not involve any study participants.
With 28 vials of each vaccine, the study would
have 95% power to detect if the vaccine vials in fact
contained 19 rather than 20 doses, assuming an SD of
1.6 and with a one-sided alpha of 0.05.
All statistical analyses were done as linear regres-
sion analyses in Stata 12.1.
Results
During 29 days, the two vaccinators opened 68 BCG
vaccine vials, 39 (57%) BCG-Denmark and 29 (43%)
BCG-Russia (see Supplementary Table). The median
number of doses obtained was 13 (range 11–17): 13
(range 11–16) for BCG-Denmark and 15 (range
12–17) for BCG-Russia. More doses were obtained
from the BCG-Russia vials than the BCG-Denmark
vials (p < 0.00001, Figure 1). There was no significant
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Figure 1. Number of doses obtained from 20-dose vials of BCG-Denmark and BCG-Russia, respectively. Guinea-Bissau, October–
November 2015.
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difference in the number of doses obtained by the
two vaccinators, neither overall nor by vaccine type
(data not shown). The number of doses obtained per
vial did not change over the study period, neither
overall, by vaccine type (Figure 1), nor by vaccinator
(data not shown).
Discussion
We found that experienced vaccinators were able to
retrieve significantly fewer infant vaccine doses from a
20-dose BCG vial than suggested by the manufac-
turers. The overall median number of doses obtained
per vial was 13. There were more doses in the BCG-
Russia vials than in the BCG-Denmark vials. Only
once was it possible to extract a maximum of 17 doses.
Strengths of the study include the use of two
different commercial vaccine preparations as well as
two highly experienced vaccinators, both with more
than 10 years of experience. The fact that there were
no differences between the two vaccinators in the
number of doses obtained for each of the two pre-
parations of BCG vaccine suggests our findings were
not due to operator-dependent artefacts but product-
related. A limitation of the study is that the results are
not directly generalisable to other settings with less
experienced staff. Less experienced vaccinators would
likely have a larger loss of vaccine due to poorer
technique with respect to reconstituting the vaccine
and withdrawing doses. Thus, we are confident that
in real-life situations the 20-dose vials contain at best
only around 13 (BCG-Denmark) and 15 (BCG-
Russia) doses, respectively.
Common sense predicts that it would be implau-
sible to obtain 20 doses of 0.05 ml each, when com-
bining freeze-dried vaccine substance with 1 ml
solvent, considering the several sources of wastage:
first, loss in solvent vial (remaining liquid); second,
dead space in needle used to reconstitute the vaccine;
third, loss in vial with reconstituted vaccine; fourth,
dead space in needle for injection; fifth, loss in de-
airing of the syringe before injection [3]. Vaccine
manufacturers are expected to overfill vials to com-
pensate for vaccine wastage attributable to dead space
in syringes to ensure that the number of doses indi-
cated on the label can be drawn from the vial [3].
Based on our figures, there is too little BCG solvent to
compensate for the wastage caused by syringes and
remaining liquid in the solvent and BCG vials.
The results are very important because using the
correct denominator to calculate open vial wastage
rates for BCG could help provide realistic wastage
targets. With a request to keep wastage for 20-dose
vials at 15% [3], an average of 17 infants should be
vaccinated with each vial to reach the target. This is
not feasible as our team could only once obtain 17
doses from a vial. If it were acknowledged that the
vials rather contain 13 doses, the 15% wastage target
would be reached with 11 infants rather than 17
infants. This would imply an adjustment to the cur-
rent practice in which opening a vial should happen
when 7–8 rather than 10–12 infants are present.
This change in perception would immediately alle-
viate pressure on health workers, no longer having to
restrict BCG vial opening as fiercely, with important
consequences for BCG vaccination coverage, and for
the mothers, who often come several times in vain
before getting their child vaccinated. For instance, in
2010 in rural Guinea-Bissau, only 38% were BCG-
vaccinated by 1 month of age, yet 25% of the BCG-
unvaccinated children had been in contact with a
health facility; many of their mothers reported having
been told to come back another day for vaccination.
Had the children been vaccinated at that contact, the
BCG vaccination coverage by 1 month would have
soared to 54% rather than 38% [4].
Timely BCG vaccination is particularly important
because BCG vaccine provided at birth has been
shown in RCTs to reduce neonatal mortality by
more than 40% [5,6]. The gain from opening a vial
of BCG just for one child may thus be considerable.
The WHO advocates BCG at birth, but it is often
given with large delays because of pressure to reduce
wastage. It has been suggested that using vials with
fewer doses would reduce wastage, but it has also
been shown that the cost of such vials is not substan-
tially lower, and decreased availability of vaccines and
increased transport and storage facility costs would
outweigh or even exceed the potential savings [7].
Thus, we recommend that a 20-dose vial of BCG
vaccine be reclassified as a ‘1-dose vial with elastic’,
which is opened for a single child, but can be
extended to vaccinate up to 13–15 children.
Conclusion
We found that in real life, experienced nurses could
only obtain 13-15 doses from 20-dose BCG vials.
Currently, to reduce vaccine wastage, in many low-
income countries a BCG vial is not opened for less
than 10-12 infants. Adjusting wastage-reducing prac-
tice to the real-life number of doses would immedi-
ately suggest vials be opened if 7 infants are present.
As BCG may have beneficial non-specific effects, the
potential gain by opening a vial even for one child
may be considerable.
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Paper context
BCG vaccine comes in vials of 20 infant doses, which
should be discarded 4–6 hours after opening. To reduce
wastage, many countries only open a vial if 10–12 eligible
infants are present. We demonstrated that in real life
trained nurses only obtain 13 doses from the vials. This
should lead to immediate adjustment of wastage-reducing
practices. As BCG vaccine may have beneficial non-specific
effects, opening a vial for one child may be highly cost-
effective.
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